clinical trial · NCT05918588
A Study to Determine the Effect of Multiple Oral Doses and Regimens of KD025 in Healthy Male and Post-menopausal Female Subjects
Kadmon, a Sanofi Company·phase1·completed·n = 32
Immune System Disorder (Healthy Volunteer)Belumosudil mesylatePlacebo
brief summary
The purpose of this study is to determine the safety, tolerability, and pharmacokinetics of multiple oral doses and regimens of KD025 in healthy male and post-menopausal female participants.
started
Nov 21, 2013
primary completion
Mar 6, 2014
completion
Mar 6, 2014
last updated
Jun 26, 2023
detailed description
Up to approximately 37 days including safety follow up period of 30 days after participant is treated with the last dose of study drug.
official title
A Phase 1, Placebo-Controlled, Double-Blind, Dose-Escalating Study to Examine the Safety and Tolerability of Multiple Doses of KD025 (Formerly Called SLX-2119) in Healthy Male and Post- Menopausal Female Subjects
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol